Pacgen Biopharmaceuticals using innovative technology in study of
RESEARCH TRIANGLE PARK, N.C., March 5 /PRNewswire/ -- Quintiles Transnational Corp. today announced it has achieved another major milestone in the management of clinical trial data -- 300 clinical trials using Electronic Data Capture (EDC).
The milestone EDC trial is a Phase II study being conducted for Pacgen Biopharmaceuticals Corporation of Vancouver, British Columbia. Pacgen is studying an anti-infective drug for the treatment of oral candidiasis. Quintiles began using EDC in 1999 and has seen acceptance of the technology accelerate since then, with more than 94 EDC trials put into production in 2007.
"At Quintiles, EDC is quickly surpassing paper in the collection of clinical trial data as customers are placing increased value on our ability to give them expert guidance in the appropriate use of this technology, as well as the potential for savings in time and cost," said Paula Brown Stafford, Executive Vice President, Global Data Management and Biostatistics, and a member of the CDISC Board of Directors. "We have been able to demonstrate for the pharmaceutical and biotech industries that EDC, when used properly, can make much better use of available resources.
"With Pacgen, we're working with an emerging biopharmaceutical company that is conducting important research in infectious diseases," she added. "Quintiles looks forward to continuing to help Pacgen further develop its pipeline."
Pacgen is a life sciences company focused on the development of
therapeutics for the treatment of infectious and inflammatory diseases. The
company's lead product, PAC-113, is an anti-fungal in a Phase II clinical
program. Pacgen also has candidates in an early stage research program. The
most advanced of these candidates is a novel peptide therapeutic, PAC-G31P,
which is currently being investigated in
|SOURCE Quintiles Transnational Corp.|
Copyright©2008 PR Newswire.
All rights reserved